Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
12/07/2024 21:15
July 12 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS INC: ENTERED PURCHASE DEAL WITH THERACELL FOR
PURCHASE
OF 50% OUTSTANDING OWNERSHIP RIGHTS & EQUITY INTERESTS IN
THERACELL LABORATORIES IKE
* ORGENESIS INC: PURSUANT TO DEAL, FOR PURCHASE OF ASSETS,
CO TO
PAY THERACELL $13 MILLION
Source text for Eikon: ID:n0001493152-24-027083
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules